# Daily Anxiety and Depressive Symptoms Linked to Cannabis-Alcohol Co-Use

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/daily-anxiety-cannabis-alcohol-co-use-black-sgm/
> **Published:** 2026-04-09T04:04:14-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:26:58-04:00
> **Clinical Summary:** Explore daily anxiety cannabis alcohol co-use among Black sexual and gender minority people and its impact on mental health and substance use patterns.

---

CED Clinical Relevance  #82High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications.
🔬 Evidence Watch  |  CED Clinic
Mental HealthCo-UseHealth DisparitiesAnxietyDepression

Journal
The International journal on drug policy

Study Type
Cohort

Population
Human participants

Why This Matters

This study provides critical insight into substance use patterns among Black sexual and gender minority individuals, a population facing compounded health disparities. Understanding the relationship between mental health symptoms and co-use patterns informs targeted clinical interventions for vulnerable populations.

Clinical Summary
This cohort study utilized ecological momentary assessment over 14 days among 521 Black SGM aged 16-35 in Chicago to examine real-time associations between anxiety/depression symptoms and same-day cannabis-alcohol co-use. The study found that daily anxiety and depressive symptoms were more strongly associated with cannabis-alcohol co-use than single-substance use on the same day. This suggests that co-use may represent a maladaptive coping strategy for acute mental health distress in this population. The EMA methodology provides valuable real-world data on temporal relationships between symptoms and substance use behaviors.

Dr. Caplan’s Take

“This reinforces what I observe clinically – patients often escalate to poly-substance use when single agents aren’t adequately addressing their distress. The temporal relationship documented here underscores the importance of addressing underlying mental health symptoms rather than focusing solely on substance use behaviors.”

Clinical Perspective
🧠 Clinicians treating Black SGM patients should screen for co-use patterns, not just individual substance use, particularly during periods of heightened anxiety or depression. Mental health interventions targeting same-day symptom management may be more effective than traditional addiction approaches for preventing problematic co-use in this population.

💬 Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

Have thoughts on this? Share it:

[𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Daily%20anxiety%20and%20depressive%20symptoms%20are%20associated%20with%20greater%20same-day%20canna...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41950751/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41950751/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Daily%20anxiety%20and%20depressive%20symptoms%20are%20associated%20with%20greater%20same-day%20canna...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41950751/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/)

📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41950751/](https://pubmed.ncbi.nlm.nih.gov/41950751/)

Table of Contents

- [FAQ](#FAQ)[Why should clinicians be concerned about cannabis-alcohol co-use in Black sexual and gender minority patients?](#Why_should_clinicians_be_concerned_about_cannabis-alcohol_co-use_in_Black_sexual_and_gender_minority_patients)
- [How does mental health symptom severity relate to substance use patterns in this population?](#How_does_mental_health_symptom_severity_relate_to_substance_use_patterns_in_this_population)
- [What makes this population particularly vulnerable to substance use-related health outcomes?](#What_makes_this_population_particularly_vulnerable_to_substance_use-related_health_outcomes)
- [How should clinicians screen for cannabis-alcohol co-use in Black SGM patients?](#How_should_clinicians_screen_for_cannabis-alcohol_co-use_in_Black_SGM_patients)
- [What treatment implications does this research suggest for clinical practice?](#What_treatment_implications_does_this_research_suggest_for_clinical_practice)
- [Related](#Related)

## FAQ

#### Why should clinicians be concerned about cannabis-alcohol co-use in Black sexual and gender minority patients?

Black SGM individuals face compounded health disparities including higher rates of substance use and mental health comorbidities. This study demonstrates that daily anxiety and depression symptoms specifically increase the likelihood of same-day cannabis-alcohol co-use, which poses greater health risks than single-substance use and requires targeted clinical attention.

#### How does mental health symptom severity relate to substance use patterns in this population?

The research shows a clear association between daily anxiety and depressive symptoms and increased cannabis-alcohol co-use on the same day. This suggests that Black SGM individuals may be using multiple substances simultaneously as a coping mechanism for acute mental health symptoms, indicating the need for integrated treatment approaches.

#### What makes this population particularly vulnerable to substance use-related health outcomes?

Black SGM individuals experience intersectional minority stress from both racial and sexual/gender identity discrimination, contributing to higher baseline mental health symptom burden. Combined with systemic barriers to [healthcare access](https://cedclinic.com/veterans-military-policy-legal-issues-cannabis-access/) and culturally competent treatment, this creates heightened vulnerability to problematic substance use patterns including co-use behaviors.

#### How should clinicians screen for cannabis-alcohol co-use in Black SGM patients?

Clinicians should specifically ask about same-day use of [cannabis and alcohol](https://cedclinic.com/can-you-mix-weed-and-alcohol/), not just individual substance use patterns, particularly when patients report elevated anxiety or depression symptoms. The ecological momentary assessment approach used in this study suggests that real-time symptom monitoring could be valuable for identifying high-risk periods for co-use.

#### What treatment implications does this research suggest for clinical practice?

The findings indicate that mental health symptoms directly predict co-use behaviors, suggesting that effective anxiety and depression treatment may reduce harmful substance use patterns. Clinicians should consider integrated treatment models that simultaneously address mental health symptoms and substance use rather than treating these conditions separately.

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

Teen [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) Mirrors Alcohol Consumption Trends – Mirage News

Explore how teen [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) parallels alcohol consumption trends, providing insights into youth substance use behaviors.

Read More

[Major study finds strong link between cannabis, anxiety and depression – Medical Xpress](https://cedclinic.com/bidirectional-cannabis-anxiety-depression-link/)

Review key findings on the association between cannabis use and mental health conditions like anxiety and depression.

[Learn More](https://cedclinic.com/bidirectional-cannabis-anxiety-depression-link/)

[Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online](https://cedclinic.com/psychiatric-outcomes-cannabis-use-disorder-comparison/)

Compare [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) with other [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) to understand differential impacts and treatment needs.

[Explore Study](https://cedclinic.com/psychiatric-outcomes-cannabis-use-disorder-comparison/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
